חזרה לתוצאות החיפוש

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

ישראלמגייס משתתפיםPHASE3

מצבים רפואיים

Obesity · Overweight

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Carey Chronis MD Pediatric, Infant and Adolescent Medicine, Ventura, California, United States

    Study coordinator · 805-642-4704
    Contact: Principal Investigator (Carey Chronis)

  • Stamford Therapeutics Consortium, Stamford, Connecticut, United States

    Study coordinator · 727-544-4842
    Contact: Principal Investigator (David Radin)

  • Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia, United States

    Study coordinator · 404-712-4731
    Contact: Principal Investigator (Daniel Hsia)

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

    Study coordinator · 312-503-1499
    Contact: Principal Investigator (Justin Ryder)

  • Velocity Clinical Research, Lafayette, Louisiana, United States

    Study coordinator · 337-519-4742
    Contact: Principal Investigator (Jibran Atwi)

  • MedPharmics, LLC, Gulfport, Mississippi, United States

    Study coordinator · 228-206-1283
    Contact: Principal Investigator (Paul Matherne)

  • Sundance Clinical Research, St Louis, Missouri, United States

    Study coordinator · 314-567-3377
    Contact: Principal Investigator (Delores Chantal Dotson)

  • Lucas Research, Inc., Morehead City, North Carolina, United States

    Study coordinator · 252-222-5700
    Contact: Principal Investigator (Kathryn Lucas)

  • Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

    Study coordinator · 412-692-6935
    Contact: Principal Investigator (Silva Arslanian)

  • Vanderbilt Health One Hundred Oaks, Nashville, Tennessee, United States

    Study coordinator · 615-322-6000
    Contact: Principal Investigator (Gitanjali Srivastava)

  • Dynamed Clinical Research, LP d/b/a DM Clinical Research, Houston, Texas, United States

    Contact: Principal Investigator (Brandon Essink)

  • La Providence Pediatrics Clinic - Chemidox Clinical Trials, Houston, Texas, United States

    Study coordinator · 833-324-3643
    Contact: Principal Investigator (Ifeyinwa Onwudiwe)

  • Martin Diagnostic Clinic, Tomball, Texas, United States

    Contact: Principal Investigator (Vicki Miller)

  • Velocity Clinical Research, Salt Lake City, South Jordan, Utah, United States

    Contact: Principal Investigator (Barbara Rizzardi)

  • Shamir Medical Center, Beer Jacob, Israel

    Contact: Principal Investigator (Marianna Rachmiel)

  • Shaare Zedek Medical Center, Jerusalem, Israel

    Contact: Principal Investigator (Floris Levy-Khademi)

  • Sheba Medical Center, Ramat Gan, Israel

    Study coordinator · 97235305015
    Contact: Principal Investigator (Noah Gruber)

  • Azienda Ospedaliero Universitaria Meyer, Florence, Italy

    Contact: Principal Investigator (Stefano Stagi)

  • Azienda Ospedaliero Universitaria Maggiore della Carità, Novara, Italy

    Contact: Principal Investigator (Ivana Rabbone)

  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento, Verona, Italy

    Contact: Principal Investigator (Claudio Maffeis)

  • Saitama Medical University Hospital, Iruma-Gun, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Toru Kikuchi)

  • Isesaki Municipal Hospital, Isesaki-shi, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Yoko Takano)

  • University Hospital,Kyoto Prefectural University of Medicine, Kawaramachidori, Kamigyo-ku, Kyoto-city, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Satoru Sugimoto)

  • Tokyo Medical Center, Meguro-Ku, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Masashi Miharu)

  • Shiga General Hospital, Moriyama, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Katsuyuki Matsui)

  • Nara Prefecture General Medical Center, Nara, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Sayaka Yoshida)

  • Osaka City General Hospital, Osaka, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Jun Mori)

  • Sagaekiminami Clinic, Saga, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Tateo Kuno)

  • Shikoku Medical Center for Children and Adults, Zentsujichó, Japan

    Study coordinator · 81120023812
    Contact: Principal Investigator (Takafumi Okada)

  • Krakowskie Centrum Medyczne - FutureMeds, Krakow, Poland

    Contact: Principal Investigator (Ewelina Malec)

  • FutureMeds - Targowek, Warsaw, Poland

    Contact: Principal Investigator (Anna Liber)

  • Instytut Diabetologii - Warsaw, Warszewo, Poland

    Contact: Principal Investigator (Ewa Pankowska)

  • FutureMeds sp. z o. o., Wroclaw, Poland

  • Barnsley Hospital NHS Foundation Trust, Barnsley, United Kingdom

    Study coordinator · 01226 432860
    Contact: Principal Investigator (Rajeev Gupta)

  • Bristol Royal Hospital for Children, Bristol, United Kingdom

    Study coordinator · 0117 342 0183
    Contact: Principal Investigator (Dinesh Giri)

  • Addenbrookes Hospital, Cambridge, United Kingdom

    Study coordinator · 07824 302285
    Contact: Principal Investigator (Ken Ong)

  • Ninewells Hospital, Dundee, United Kingdom

    Study coordinator · (44138) 238-8385
    Contact: Principal Investigator (Nicholas Conway)

  • Northwick Park Hospital, Harrow, United Kingdom

    Study coordinator · 020 8864 3232
    Contact: Principal Investigator (Nilanjana Ray)

  • Hull Royal Infirmary, Hull, United Kingdom

    Study coordinator · 01482 875875
    Contact: Principal Investigator (Verghese Mathew)

  • Alder Hey Children's Hospital, Liverpool, United Kingdom

    Study coordinator · (447) 971-6250 x31
    Contact: Principal Investigator (Senthil Senniappan)
מובילי המחקר

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

    Study Director

    Eli Lilly and Company

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)פנייה לחוקר (אימייל)